Trending...
- BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers
- Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
- The Kryder Law Group, LLC Report Reveals Commercial Air Travel Is Safer Than You Think
SEATTLE, May 13, 2024 ~ Seattle, WA- With the number of pediatric inflammatory bowel disease (IBD) diagnoses increasing globally, a clinical trial in Seattle is aiming to revolutionize treatment approaches through deep molecular profiling. The Seattle STRIDE study, a collaboration between Seattle Children's Research Institute and the Allen Institute for Immunology, has begun recruiting volunteers for its three-year study.
The trial plans to enroll 200 participants and utilize genomic tools to analyze tissue samples from routine tests. These single-cell analysis methods will provide a detailed understanding of how the immune system behaves in patients with IBD and how it responds to specific drug treatments over time.
According to Dr. Betty Zheng, an assistant professor of pediatrics at Seattle Children's and the principal investigator of the study, this deep immune profiling could offer an unprecedented view of the disease and potentially lead to new and improved treatments.
"IBD is a complex disease and we still have a limited understanding of its molecular mechanisms," said Dr. Zheng. "By partnering with the Allen Institute, we hope to gain a detailed view of these mechanisms in order to find better ways of treating our patients."
More on Washingtoner
The exact causes and progression of IBD, a chronic inflammatory condition affecting the digestive tract, have remained elusive. It is believed that a combination of genetic factors, immune dysregulation, and environmental or dietary factors may play a role.
In children, IBD can be more aggressive and difficult to treat compared to adults. Approximately 30% of pediatric IBD patients do not respond to initial treatments and nearly half will eventually become resistant to their current treatments. This can lead to serious consequences such as impaired growth, mental health issues, and missed educational and social activities.
Dr. Zheng believes that a deeper understanding of the molecular workings of the disease could lead to personalized treatment strategies instead of relying on one-size-fits-all approaches.
"Some children respond well to first-line therapies while others require multiple treatments or do not respond at all," she explained. "This is a major challenge in the clinic."
In addition to potentially improving treatment options, a deep dive into the molecular mechanisms of IBD could also uncover new pathways of inflammation that could be targeted for the development of new drugs.
More on Washingtoner
Dr. Adam Savage, an assistant investigator at the Allen Institute for Immunology, emphasized the importance of exploring these unknown pathways.
"There is a universe of information that is not being seen," he said.
To uncover this information, Dr. Savage and his team will utilize advanced technologies developed at the Allen Institute for Immunology to identify and pinpoint immune cells and molecules within tissue samples collected during routine hospital visits. By analyzing these samples over time, they hope to gain insight into how the disease progresses and how patients respond to treatment.
While the study may involve complex data and advanced technologies, Dr. Savage reminds us that the ultimate goal is to improve the lives of patients.
"We may look at data on computers or work in labs, but when we see the patients we are trying to help, it serves as a powerful reminder of why we do what we do - to have a real impact on patients' lives," he said.
Families interested in participating in the Seattle STRIDE study can find more information on their website. The study offers hope for improved treatments and better outcomes for children with IBD.
The trial plans to enroll 200 participants and utilize genomic tools to analyze tissue samples from routine tests. These single-cell analysis methods will provide a detailed understanding of how the immune system behaves in patients with IBD and how it responds to specific drug treatments over time.
According to Dr. Betty Zheng, an assistant professor of pediatrics at Seattle Children's and the principal investigator of the study, this deep immune profiling could offer an unprecedented view of the disease and potentially lead to new and improved treatments.
"IBD is a complex disease and we still have a limited understanding of its molecular mechanisms," said Dr. Zheng. "By partnering with the Allen Institute, we hope to gain a detailed view of these mechanisms in order to find better ways of treating our patients."
More on Washingtoner
- Rio Bela Cosmetics Launches Inclusive Line of Organic Skincare Products
- The 7 Visibility Problems Costing Independent Hotels Thousands Every Month
- Viola's Babygirl's, LLC Proudly Announces Teri Tobin's Soulful New Christmas EP "Home For The Holidays"
- Stoxtel Introduces High-Throughput "Matrix" Engine to Address Mexico's Crypto Trading Volatility
- UK Financial Ltd Sets Listing Date With Catex Exchange For The Listing Of Mayacat The World's First Ever Gold Backed ERC 3643 "SEC Ready" Token
The exact causes and progression of IBD, a chronic inflammatory condition affecting the digestive tract, have remained elusive. It is believed that a combination of genetic factors, immune dysregulation, and environmental or dietary factors may play a role.
In children, IBD can be more aggressive and difficult to treat compared to adults. Approximately 30% of pediatric IBD patients do not respond to initial treatments and nearly half will eventually become resistant to their current treatments. This can lead to serious consequences such as impaired growth, mental health issues, and missed educational and social activities.
Dr. Zheng believes that a deeper understanding of the molecular workings of the disease could lead to personalized treatment strategies instead of relying on one-size-fits-all approaches.
"Some children respond well to first-line therapies while others require multiple treatments or do not respond at all," she explained. "This is a major challenge in the clinic."
In addition to potentially improving treatment options, a deep dive into the molecular mechanisms of IBD could also uncover new pathways of inflammation that could be targeted for the development of new drugs.
More on Washingtoner
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
- Althea Gibson Honored as Final Release in U.S. Mint's American Women Quarters Program
- Lokal Media House Achieves Yelp Platinum Partner Status
- Carrington College in Spokane Announces New Campus Director
- World's First AI-Native Industrial Facility is Under Construction by Carbon AMS with rhobot.ai
Dr. Adam Savage, an assistant investigator at the Allen Institute for Immunology, emphasized the importance of exploring these unknown pathways.
"There is a universe of information that is not being seen," he said.
To uncover this information, Dr. Savage and his team will utilize advanced technologies developed at the Allen Institute for Immunology to identify and pinpoint immune cells and molecules within tissue samples collected during routine hospital visits. By analyzing these samples over time, they hope to gain insight into how the disease progresses and how patients respond to treatment.
While the study may involve complex data and advanced technologies, Dr. Savage reminds us that the ultimate goal is to improve the lives of patients.
"We may look at data on computers or work in labs, but when we see the patients we are trying to help, it serves as a powerful reminder of why we do what we do - to have a real impact on patients' lives," he said.
Families interested in participating in the Seattle STRIDE study can find more information on their website. The study offers hope for improved treatments and better outcomes for children with IBD.
Filed Under: Business
0 Comments
Latest on Washingtoner
- New 2025–2026 Energy Rebates: Squeaks Services Explains How to Qualify
- CCHR's New Documentary Prescription for Violence Highlights Overlooked Safety Warnings
- Men's Health Network Announces a New Feature to Support the Well-Being of Men When and Where They Are through Text Alerts
- Comp-U-Floor Unveils Powerful New Commercial Module
- Revenue Optics Announces the Appointment of Sonal Chowdhury as Senior Manager – Strategic Operations
- How California Convinces Buyers Not to Purchase New Cars — and How This Hurts Dealers
- Zaaz Hosts First-of-Its-Kind Creator Series Event in Seattle Studios
- Tax Fears and Political Volatility Drive Wealthy UK Residents to Consider Leaving, La Vida Survey Shows
- Titan Steel Buildings Expands Nationwide to Deliver Large Steel Warehouses and Industrial Facilities
- AI Robots Deliver 145% Annualized Returns Amid Market Volatility
- Kaltra Removes Size Barriers for Microchannel Coils with Fully Integrated Large-MCHE Production
- Premium Kitchen Remodeling Services in Camas, WA
- Spokane: Council Members Propose Budget Amendment to Fund Libraries and Public Safety
- Guests Can Save 10 Percent Off New Vacation Rental Homes at KeysCaribbean's Village at Hawks Cay Villas
- Paylode Acquired by Moved to Power the Next Generation of Ancillary Revenue Automation
- Applications Now Being Accepted for Tacoma Municipal Court Judge No. 2 Position
- Spokane: New Automated Traffic Safety Cameras Installed at Intersection of Mission and Greene
- Global Preschool Giants Unite to Celebrate the 12th Anniversary of Badanamu's Hit Song "Ponytail"
- City of Tacoma Observes Thanksgiving on November 27 and 28
- Tacoma Municipal Court Judge Drew Henke Announces Retirement After Decades of Public Service